GET DAILY SIGNALSAdaptive Biotechnologies (ADPT) Delivers Q3 2026 Beat and First GAAP Profit
Key Takeaways
- Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million, up 39% year over year and well above the roughly $71.6 million consensus estimate.
- Earnings per share (EPS) came in at $0.02, a sharp swing above the consensus expectation of a $0.10 loss, marking a rare GAAP-profitable quarter for the company.
- clonoSEQ test volume grew 46% year over year to 39,587 tests, while the MRD (Minimal Residual Disease) business generated $72.6 million in revenue.
- Total company adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) turned positive at $14.3 million, with the MRD segment contributing $15.1 million.
- Management raised full-year 2026 MRD revenue guidance to $276 million to $286 million, up from the prior $268 million to $278 million range.
- For additional context on this ticker, you can explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- To discover data-driven trading ideas across the market, explore Trending AI Robots.
Why the Quarter Matters
Adaptive Biotechnologies is a commercial-stage biotechnology company centered on the clonoSEQ assay, which detects and monitors MRD in blood cancers through next-generation sequencing. Investors have tracked the company's progress in narrowing losses while growing test volumes, and the third quarter appeared to mark a meaningful shift. Given Adaptive's history of cash burn during the scaling of its clinical and biopharmaceutical operations, this report served as an important check on whether revenue growth could support broader profitability. The outcome also reflects ongoing developments in the MRD diagnostics space, including reimbursement patterns, guideline changes, and demand from drug developers.
Quarterly Results in Detail
Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million, a 39% increase from the prior-year period and ahead of the consensus estimate of roughly $71.6 million. MRD revenue reached $72.6 million, while Immune Medicine revenue contributed $11.3 million, largely from the company's target discovery agreement with Pfizer. clonoSEQ test volume rose 46% year over year to 39,587 tests. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On the bottom line, the company posted GAAP net income of $2.8 million, or $0.02 per share, compared with consensus expectations of a $0.10 loss per share. This represents a notable move toward profitability for a business that had been consistently unprofitable. Total company adjusted EBITDA was positive at $14.3 million, with the MRD segment generating $15.1 million in adjusted EBITDA, up from $7 million a year earlier. Sequencing gross margin improved to 73%, up from 66%.
Management raised its full-year 2026 MRD revenue guidance to $276 million to $286 million, up from the previous $268 million to $278 million range, and now expects full-year operating expenses of approximately $350 million.
Market Reaction and Outlook
Heading into the report, sentiment toward Adaptive Biotechnologies had been cautiously optimistic as the company repeatedly beat estimates in prior quarters while steadily narrowing losses. The third quarter's combination of a top-line beat, positive EPS, and company-wide adjusted EBITDA profitability represented a stronger result than many analysts had modeled, and the raised full-year guidance reinforced confidence in the growth trajectory. Key drivers included accelerating clonoSEQ test volumes, expanding adoption of blood-based testing, and progress in the MRD pharmaceutical business. The main questions now center on whether the company can sustain profitability in the fourth quarter and beyond, given that management cautioned it does not currently anticipate GAAP net income or positive EPS for the fourth quarter or the full year.
Forward Catalysts to Watch
Looking ahead, investors will focus on whether Adaptive Biotechnologies can convert its momentum into durable, company-wide profitability. Management has signaled that the fourth quarter may not repeat the third quarter's GAAP profit, so the path of adjusted EBITDA and operating leverage will remain central.
Several specific catalysts stand out. First, the company's maintenance bundle submission is now under review with MolDx, and progress on reimbursement expansion could meaningfully influence future clinical testing revenue and average selling prices. Second, the MRD pharmaceutical business continues to grow, with backlog of approximately $270 million, up 34% year over year, and 191 active studies providing visibility into future sequencing revenue. Third, the shift toward blood-based testing and increased community-setting adoption remain important volume drivers, as they lower barriers to ordering and support more frequent serial monitoring. Finally, investors should watch the company's cash position and expense discipline, particularly as it weighs strategic options for its Immune Medicine segment. These factors, rather than any single quarterly figure, are likely to shape the company's narrative over the coming quarters.
Enhancing Research with Tickeron Tools
In my own analysis of earnings reports like this one, I often turn to Tickeron's AI-powered tools to cross-check patterns and compare performance across peers. The AI Screener stands out for quickly filtering stocks by fundamentals, technical signals, and industry trends, which helps surface context that might otherwise take hours to compile manually. It has become a regular part of my workflow when evaluating biotech names and their post-earnings trajectories.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ADPT in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 27, 2026
ADPT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 51 similar instances where the stock broke above the upper band. In 46 of the 51 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 63 cases where ADPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ADPT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on ADPT as a result. In 74 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for ADPT just turned positive on October 27, 2026. Looking at past instances where ADPT's MACD turned positive, the stock continued to rise in 46 of 54 cases over the following month. The odds of a continued upward trend are 85%.
ADPT moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ADPT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +6.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADPT advanced for three days, in 237 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.828) is normal, around the industry mean (66.911). P/E Ratio (-66.775) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (13.966) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ADPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development of an immune medicine platform
Industry MedicalSpecialties
Advertisement